GFAP and Lewy body dementia: The differential power of blood biomarkers to differentiate AD from DLB seems to be rather cohort-dependent.14 Although, in a previous study P-tau181 and GFAP have been found to be associated with CSF amyloid status, another study reported no association of any of the above-mentioned biomarkers with amyloid PET.